Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
51 participants
INTERVENTIONAL
2008-03-31
2012-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms
NCT00403546
A Study of Ziprasidone for the Treatment of Psychosis in Patients Who Had Already Had Benefits From Ziprasidone Treatment in a Previous Study
NCT00645320
Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia
NCT00257192
Safety And Tolerability Of Ziprasidone In Adolescents With Schizophrenia
NCT00265382
Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics
NCT00458211
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ziprasidone
Patients will be treated with Ziprasidone for 6 months
ziprasidone
20-160 mg/d
Placebo
Patients will be treated with placebo for 6 months
placebo
placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ziprasidone
20-160 mg/d
placebo
placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* clinically referred
Exclusion Criteria
* history of syncope
16 Years
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yale University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Scott W Woods, MD
Role: PRINCIPAL_INVESTIGATOR
Yale University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California at San Diego
La Jolla, California, United States
University of California at Los Angeles
Los Angeles, California, United States
University of California, San Francisco
San Francisco, California, United States
Yale University School of Medicine
New Haven, Connecticut, United States
Emory University
Atlanta, Georgia, United States
Beth Israel Deaconess Hospital
Boston, Massachusetts, United States
University of Massachusetts
Worcester, Massachusetts, United States
Wayne State University School of Medicine
Detroit, Michigan, United States
North Shore, Long Island Jewish Health System
Glen Oaks, New York, United States
University of North Carolina
Chapel Hill, North Carolina, United States
University of Calgary
Calgary, Alberta, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IIR GA1281GE
Identifier Type: -
Identifier Source: secondary_id
0801003386
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.